Quick Listen: Scrip’s Five Must-Know Things
Executive Summary
Join us for an audio roundup of major events in the global biopharma industry over the past week, as reported by Scrip.
Take a brief audio tour around Scrip's Five Must-Know Things, this time covering key developments reported in the business week ended 25 September 2020.
Significant new data from ESMO, Pfizer's changing oncology strategy, and a critical drug pricing hearing in the US are among the items on the agenda in this episode.
This and other Informa Pharma Intelligence podcasts are also now voice-accessible as a skill on Alexa smart speakers and the Alexa app, under the "Business and Finance" category. Just say “Alexa, Open Informa - Pharma Intelligence" and you can then ask for a specific podcast.
Stories mentioned in this episode:
(Also see "ESMO: A Tale Of Two CDK 4/6 Inhibitors With monarchE Success and Failure For PALLAS" - Scrip, 21 Sep, 2020.)
(Also see "ESMO: Pfizer's Lorbrena Makes Case To Claim ALK+ Lung Cancer CROWN" - Scrip, 20 Sep, 2020.)
(Also see "Amgen’s KRAS Inhibitor Shows Durability; Pivotal Data Possible This Year" - Scrip, 21 Sep, 2020.)
(Also see "Pfizer Oncology Pipeline Shows Pivot To Targeted Therapies" - Scrip, 22 Sep, 2020.)
(Also see "Why Is Congress Targeting These Six Medicines In Drug Price Hearing?" - Scrip, 23 Sep, 2020.)